ReviewInfectious diseases & immunity2026
Unraveling chikungunya's viral tapestry through molecular mechanisms and clinical insights.
Review in Infectious diseases & immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya fever (CHIKF) is an arthropod-borne viral disease caused by the chikungunya virus (CHIKV). Patients typically present with fever and symmetric distal polyarthralgia, which may progress to chronic joint sequelae. This review was conducted to systematically examine CHIKF's virological characteristics, immunopathogenic mechanisms, global and regional epidemiology, and clinical manifestations as well as diagnostic approaches and treatment options. CHIKV may be present in areas previously considered nonendemic, as increased international travel, high urban population densities, and favorable vector ecology facilitate viral transmission. Effective CHIKF control requires the implementation of enhanced surveillance, targeted vector control measures, and standardized clinical management protocols. Considering CHIKV's genomic diversity and immune-driven pathogenesis and the wide spectrum of acute and chronic disease conditions, continuous monitoring and adaptive control measures tailored to specific settings are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.